Merck & Co., Inc.
HealthcareNYSE:MRK · New York Stock Exchange
-$0.74 today
Vol 4.66M · Avg 9.70M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$65.6B of revenue converted into $8.9B of net income for the selected period. Gross margin is 75.9% and net margin is 13.5%, showing how much revenue survives after costs and taxes. EPS is $3.55, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $64.9B +1.2% | $64.2B +6.7% | $60.1B +1.4% | $59.3B +21.7% | $48.7B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $18.2B +19.8% | $15.2B -5.8% | $16.1B -7.4% | $17.4B +27.8% | $13.6B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $46.7B -4.6% | $49.0B +11.3% | $44.0B +5.1% | $41.9B +19.4% | $35.1B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 72.0% -4.3pp | 76.3% +3.1pp | 73.2% +2.5pp | 70.6% -1.4pp | 72.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $12.5B -30.2% | $17.9B -41.2% | $30.5B +125.4% | $13.5B +10.6% | $12.2B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $10.7B +6.2% | $10.1B +2.2% | $9.9B +2.2% | $9.7B +2.8% | $9.4B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $23.2B -19.2% | $28.8B -29.9% | $41.0B +74.0% | $23.6B +7.8% | $21.9B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.8B +29.8% | $4.5B +16.2% | $3.9B -0.9% | $3.9B +21.6% | $3.2B | $374.2M | $1.2B | $631.8M |
| EBITDA | $28.3B +9.9% | $25.7B +272.2% | $6.9B -67.6% | $21.3B +19.1% | $17.9B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 43.5% +3.5pp | 40.1% +28.6pp | 11.5% -24.5pp | 36.0% -0.8pp | 36.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $23.5B +16.1% | $20.2B +584.5% | $3.0B -83.8% | $18.3B +38.5% | $13.2B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 36.2% +4.7pp | 31.5% +26.6pp | 4.9% -25.9pp | 30.8% +3.7pp | 27.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $343.0M -17.3% | $415.0M +13.7% | $365.0M +132.5% | $157.0M +336.1% | $36.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.4B +6.8% | $1.3B +10.9% | $1.1B +19.1% | $962.0M +19.4% | $806.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$2.4B -748.8% | -$285.0M +73.2% | -$1.1B +42.1% | -$1.8B -370.3% | $680.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $21.1B +5.7% | $19.9B +955.4% | $1.9B -88.5% | $16.4B +18.5% | $13.9B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 32.4% +1.4pp | 31.1% +27.9pp | 3.1% -24.6pp | 27.7% -0.8pp | 28.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $2.8B +0.0% | $2.8B +85.4% | $1.5B -21.2% | $1.9B +26.1% | $1.5B | $1.3B | -$1.6B | $745.2M |
| Net Income | $18.3B +6.6% | $17.1B +4589.6% | $365.0M -97.5% | $14.5B +11.3% | $13.0B | $4.9B | $4.8B | $4.7B |
| Net Margin | 28.1% +1.4pp | 26.7% +26.1pp | 0.6% -23.9pp | 24.5% -2.3pp | 26.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $7 +8.0% | $7 +4728.6% | $0 -97.6% | $6 +11.0% | $5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $7 +8.0% | $7 +4714.3% | $0 -97.5% | $6 +11.1% | $5 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $2.5B -1.2% | $2.5B -2.9% | $2.6B +3.0% | $2.5B +0.1% | $2.5B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $2.5B -1.3% | $2.5B -0.2% | $2.5B +0.2% | $2.5B +0.2% | $2.5B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Novartis AG
NYSE:NVS
$292.83B
AstraZeneca PLC
NYSE:AZN
$278.74B
Novo Nordisk A/S
NYSE:NVO
$196.44B
Amgen Inc.
NASDAQ:AMGN
$191.12B
Thermo Fisher Scientific Inc.
NYSE:TMO
$174.59B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.61B
Abbott Laboratories
NYSE:ABT
$153.01B
Pfizer Inc.
NYSE:PFE
$149.30B
GSK plc
NYSE:GSK
$106.61B
Sanofi
NASDAQ:SNY
$106.50B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MRK generate?
Merck & Co., Inc. (MRK) reported $64.93B of revenue in fiscal 2025.
Is MRK profitable?
Merck & Co., Inc. (MRK) reported $18.25B of net income, with a net margin of 28.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.